AstraZeneca has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest healthcare deal on record.
AstraZeneca, valued at $140 billion, is the U.K.’s biggest drugmaker by market capitalization and has developed treatments for conditions including cancer and cardiovascular disease. Gilead, worth $96 billion at Friday’s close, is the creator of a drug that has received U.S. approval for use with coronavirus patients.
Shares of AstraZeneca have risen about 41% over the last 12 months. Shares of Gilead gained about 19% over the period.
AstraZeneca has been claiming for years that they could turn things around without a major purchase or merger..Wall St was skeptical - AstraZeneca approaches Gilead about potential merger
المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
AstraZeneca approached Gilead about potential merger - Bloomberg NewsAstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc about a potential merger, Bloomberg News reported on Sunday, citing people familiar with the matter. Hope combined R&D could expedite coronavirus vaccine. That's an interesting news, but it may be too early Of course they did. THE ONLY ONES GETTING RICHER WHILE THE POOR BECOMES MORE IMPOVERISHED....
اقرأ أكثر »
AstraZeneca approached Gilead about potential merger - Bloomberg NewsAstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc about a potential merger, Bloomberg News reported on Sunday, citing people familiar with the matter. Hope combined R&D could expedite coronavirus vaccine. That's an interesting news, but it may be too early Of course they did. THE ONLY ONES GETTING RICHER WHILE THE POOR BECOMES MORE IMPOVERISHED....
اقرأ أكثر »